Scinovex
review Open AccessTop 1% cited

Molecular chess? Hallmarks of anti-cancer drug resistance

BMC Cancer · 2017 · Vol. 17(1) · pp. 10–10
Ian A. CreePeter Charlton

Abstract

The oncologist is now required to be at least one step ahead of the cancer, a process that can be likened to 'molecular chess'. Thus, as well as an increasing role for predictive biomarkers to clinically stratify patients, it is becoming clear that personalised strategies are required to obtain best results.

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchColorectal Cancer Treatments and StudiesSurgical oncologyDrug resistanceMedicineCancer drugsDrugCancerResistance (ecology)BioinformaticsOncologyPharmacology

MeSH terms

HumansMedical OncologyNeoplasmsDrug Resistance, NeoplasmPrecision Medicine
Citations
327
FWCI
22.08
field-weighted impact
References
102
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.